RBC Capital upgraded PTC Therapeutics (PTCT) to Outperform from Sector Perform with a price target of $63, up from $39.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Partners with Novartis for Huntington’s Program
- PTC Therapeutics enters global license, collaboration agreement with Novartis
- PTC Therapeutics Sells Priority Review Voucher for $150M
- PTC Therapeutics price target raised to $52 from $48 at Baird
- PTC Therapeutics to sell Priority Review Voucher for $150M